Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Sponsor: Janssen Research & Development, LLC
Summary
The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\[s\]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with relapsed or refractory multiple myeloma and extramedullary disease (EMD) (Part 3).
Official title: A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
228
Start Date
2020-12-15
Completion Date
2026-10-27
Last Updated
2026-01-16
Healthy Volunteers
No
Conditions
Interventions
Talquetamab
Talquetamab will be administered by subcutaneous (SC) injection.
Teclistamab
Teclistamab will be administered by SC injection.
Locations (40)
University of Alabama at Birmingham, Comprehensive Cancer Center
Birmingham, Alabama, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
Emory University
Atlanta, Georgia, United States
Mayo Clinic
Rochester, Minnesota, United States
Washington University St. Louis School Medicine Siteman Cancer Center
St Louis, Missouri, United States
Mount Sinai Medical Center
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Atrium Health
Charlotte, North Carolina, United States
Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
Oregon Health And Science University
Portland, Oregon, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
St Vincents Hospital Melbourne
Fitzroy, Australia
Royal Perth Hospital
Perth, Australia
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Alberta Health Services
Edmonton, Alberta, Canada
Princess Margaret Cancer Centre University Health Network
Toronto, Ontario, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Hadassah Medical Center
Jerusalem, Israel
Sheba Medical Center
Ramat Gan, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Kanazawa University Hospital
Kanazawa, Japan
Nagoya City University Hospital
Nagoya, Japan
Osaka University Hospital
Osaka, Japan
Tohoku University Hospital
Sendai, Japan
Japanese Red Cross Medical Center
Shibuya City, Japan
Seoul National University Hospital
Seoul, South Korea
Severance Hospital Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
The Catholic University of Korea Seoul St Marys Hospital
Seoul, South Korea
Hosp. Univ. Germans Trias I Pujol
Badalona, Spain
Hosp Clinic de Barcelona
Barcelona, Spain
Inst. Cat. Doncologia-H Duran I Reynals
L'Hospitalet de Llobregat, Spain
Hosp Univ Fund Jimenez Diaz
Madrid, Spain
UNIV. HOSP. October 12
Madrid, Spain
Clinica Univ. de Navarra
Pamplona, Spain
Hosp Clinico Univ de Salamanca
Salamanca, Spain
Hosp. Univ. Marques de Valdecilla
Santander, Spain